Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
RecruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
April 1, 2014
Primary Completion Date
August 1, 2025
Study Completion Date
August 3, 2026
Conditions
Carcinoma, HepatocellularImmunotherapy
Trial Locations (1)
250012
RECRUITING
Qilu hospital of Shandong university, Jinan
All Listed Sponsors
lead
Qilu Hospital of Shandong University
OTHER
NCT06571396 - Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter